



## **SCIGEN STRENGTHENS POSITION AS A GLOBAL MANUFACTURER OF BIOSIMILARS FOLLOWING ACQUISITION OF GCSF AND EPO**

**Singapore and Sydney. Wednesday 21<sup>st</sup>, June 2006.** Singapore biopharmaceutical company SciGen Limited (ASX:SIE) has today announced that it has secured the rights to manufacture, distribute and market GCSF, used to treat the symptoms of chemotherapy, and EPO, used to treat kidney disease, through a technology transfer agreement with Intas Pharmaceutical Ltd.

SciGen announced last month (*SciGen Ltd signs an exclusive worldwide supply agreement for GCSF & EPO – 2 May 2006*) that it had signed an exclusive worldwide agreement with ACL Biopharm, Intas research & development partner, for the bulk supply of GCSF and EPO.

The technology transfer agreement will now allow SciGen the freedom to manufacture its own product supplies for worldwide commercialization using its existing and future sale and marketing channels. The world market for GCSF and EPO is in excess of US\$4 billion and USD\$10 billion dollars per annum respectively. With its growing product portfolio, SciGen aims to capture 10% of the worldwide market starting with the Asia Pacific region and moving on, in parallel, to the rest of the world including Europe, the United States and Japan.

In consideration for acquiring the rights to both products, SciGen will pay one single license fee. The specific terms of the agreement are under confidentiality between the two parties. The payment will be drawn from the credit facility made available by Bioton S.A of Poland which owns 90.5% of the company. It will therefore not impact on the company's cash position which is also being supplemented through increasing sales revenue.

Intas is free to continue producing both products for its own sales' channels. Additionally, Intas may use SciGen's manufacturing facility in India to accommodate any additional manufacturing capacity it requires.

Saul Mashaal, CEO of SciGen said the deal significantly enhances the company's position as an independent manufacturer of Biosimilar products, also known as BioGeneric.

"SciGen is developing into a major player in Biosimilar drug manufacturing with our portfolio of products continuing to grow."

"We now have seven Biosimilar products in our portfolio with the worldwide rights to manufacture and commercialize. Through the establishment and up-scaling of our own manufacturing sites in India and Israel and a joint venture in China, SciGen is well placed to independently produce its own products and implement an aggressive growth strategy."

### **Further information:**

#### **[About SciGen](#)**

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen’s competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong, and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

**Further information:**

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800 +61 417 382 391 (mobile) rwilson@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)